Literature DB >> 32374251

Genomic profiling of Escherichia coli isolates from bacteraemia patients: a 3-year cohort study of isolates collected at a Sydney teaching hospital.

Priyanka Hastak1,2, Max L Cummins2, Thomas Gottlieb3,4, Elaine Cheong4, John Merlino3,4, Garry S A Myers2, Steven P Djordjevic1,2, Piklu Roy Chowdhury2,1.   

Abstract

This study sought to assess the genetic variability of Escherichia coli isolated from bloodstream infections (BSIs) presenting at Concord Hospital, Sydney during 2013-2016. Whole-genome sequencing was used to characterize 81 E. coli isolates sourced from community-onset (CO) and hospital-onset (HO) BSIs. The cohort comprised 64 CO and 17 HO isolates, including 35 multidrug-resistant (MDR) isolates exhibiting phenotypic resistance to three or more antibiotic classes. Phylogenetic analysis identified two major ancestral clades. One was genetically diverse with 25 isolates distributed in 16 different sequence types (STs) representing phylogroups A, B1, B2, C and F, while the other comprised phylogroup B2 isolates in subclades representing the ST131, ST73 and ST95 lineages. Forty-seven isolates contained a class 1 integron, of which 14 carried bla CTX -M-gene. Isolates with a class 1 integron carried more antibiotic resistance genes than isolates without an integron and, in most instances, resistance genes were localized within complex resistance loci (CRL). Resistance to fluoroquinolones could be attributed to point mutations in chromosomal parC and gyrB genes and, in addition, two isolates carried a plasmid-associated qnrB4 gene. Co-resistance to fluoroquinolone and broad-spectrum beta-lactam antibiotics was associated with ST131 (HO and CO), ST38 (HO), ST393 (CO), ST2003 (CO) and ST8196 (CO and HO), a novel ST identified in this study. Notably, 10/81 (12.3 %) isolates with ST95 (5 isolates), ST131 (2 isolates), ST88 (2 isolates) and a ST540 likely carry IncFII-IncFIB plasmid replicons with a full spectrum of virulence genes consistent with the carriage of ColV-like plasmids. Our data indicate that IncF plasmids play an important role in shaping virulence and resistance gene carriage in BSI E. coli in Australia.

Entities:  

Keywords:  E. coliST8196; ESBL; Escherichia coli; IS26; IncF plasmids; bacteraemia; blaCTX-M; blood stream infections; class 1 integrons; fluoroquinolone resistance; multidrug resistance; qnrB4

Mesh:

Substances:

Year:  2020        PMID: 32374251      PMCID: PMC7371115          DOI: 10.1099/mgen.0.000371

Source DB:  PubMed          Journal:  Microb Genom        ISSN: 2057-5858


Data Summary

The genome sequences of the isolates included in this paper have been made accessible via GenBank, under project ID PRJNA480723. A list of individual accession numbers for the assembled genomes is provided in File S1. The genome sequence of the novel ST8196 was registered in Enterobase and is searchable using the sequence type numbers and Uber strain IDs ESC_IA6781AA and ESC_IA7243AA. All online databases were accessed through portals on the Centre Of Genomic Epidemiology website (http://www.genomicepidemiology.org/). We report on the genomic surveillance of 81 isolates collected from patients treated for bloodstream infections (BSIs) at the Concord Repatriation Hospital in Sydney, Australia between January 2013 and March 2016. Our data describe the population dynamics and highlight a segregation between virulent and drug-resistant clonal lineages in the cohort, akin to trends reported recently in a study on a cohort of more than 1500 invasive isolates collected over 11 years in the UK. Our study identifies a novel sequence type of , ST8196, within the ST131 clonal cluster, and the possible role of large ColV-like IncF plasmids in shaping the virulence and resistance profiles of isolates in this cohort. We additionally present compelling evidence on the active role played by IS26 in the ongoing evolution and clustering of antimicrobial resistance genes in from both community-onset (CO) and hospital-onset (HO) BSIs. Collectively, our results highlight why surveillance protocols that target the mobilome are needed to better understand features that distinguish CO and HO infections.

Introduction

is a major cause of bloodstream infections (BSIs), dominating the list of Gram-negative pathogens associated with bacteraemia and sepsis globally [1]. In 2017, treatment costs for patients with sepsis in Australian intensive care units were estimated to be at least USD $846 million [2]. In that year, 55.2 % of Gram-negative BSIs were caused by E. coli, of which 83.6 % were from community and 16.4 % from hospitalized patients [3]. Nationwide, the incidence of multidrug resistance associated with BSIs increased from 11.8 % in 2013 [4] to 21.9 % in 2017 [3]. This was also accompanied by an increase in the frequency of the isolation of multidrug-resistant (MDR) displaying resistance to fluoroquinolones and extended-spectrum beta-lactams [3]. Extra-intestinal pathogenic (ExPEC) are usually associated with BSIs and sepsis. ExPEC causing human infections are often characterized by the presence of P and S fimbriae that facilitate human cell attachment, toxins and cytonecrotic factors that enable invasion and subsequent damage, iron acquisition systems, serum resistance proteins [5, 6], capsular polysaccharides and lipopolysaccharides (LPS) that support survival in the host. BSIs predominantly have a community onset, with urinary tract infections (UTIs) being the most frequently reported principal clinical manifestation [3, 7]. Uropathogenic (UPEC) are a subgroup of ExPEC that are adept at colonizing the urethra and ascending into the urinary bladder causing cystitis. A 3-month sentinel surveillance of bacteraemia cases in the UK in 2012/2013, which included 35 hospitals, linked 51.2 % of the cases to UTI [8]. The first-line drugs used to treat UTI in Australia include trimethoprim, amoxicillin/clavulanate and cephalexin. Genes conferring resistance to trimethoprim are often present as gene cassettes on class 1 integrons, a globally disseminated mobile genetic element best known for its role in the rapid evolution of MDR pathogens [9-11]. Within enterobacterial genomes, class 1 integrons are frequently detected in regions where resistance genes cluster together, forming resistance loci. Hence they serve as a reliable proxy for the identification of multiple drug resistant genomes within cohorts of bacteria collected from clinical settings [12], food animals [13-15] and the environment [16]. Increasing resistance to aminoglycosides, extended-spectrum beta-lactams, fluoroquinolones and trimethoprim is a major threat to the treatment of infections, including BSIs [17-21]. Plasmids play a major role in driving the evolution of pathogens resistant to these antibiotics through the rapid dispersal of virulence and antibiotic resistance genes [22, 23] within enterobacterales. Examples of plasmid-mediated rapid pathogen evolution include the establishment of enterotoxigenic (ETEC) [24, 25] and enteroinvasive (EIEC) [26] pathotypes, which cause watery diarrhoea and bacillary (often bloody) dysentery, respectively. Globally, the most predominant ExPEC sequence types (STs) associated with UTI include ST69, ST73, ST95 and ST131 [27, 28]. Specifically, the ST131 lineage is recognized as a significant aetiological agent of UTI, pyelonephritis and urosepsis [29, 30]. The wide distribution of ST131, together with relatively higher numbers of drug resistance and virulence genes, has made it the most well-studied ExPEC lineage [31, 32]. The emergence of MDR BSIs is often associated with isolates that have acquired genes encoding extended-spectrum beta-lactamases (ESBLs), particularly bla CTX-M. There are over 100 allelic variants of bla CTX-M [33-35] and different alleles predominate in , depending on several factors, including geographical location [36]. BSIs in Argentina, South Africa, Turkey, Belgium, China, Taiwan and Australia are typically caused by that carry bla CTX-M-2, bla CTX-M-3 and bla CTX-M-15 [37-39]. Surveillance of antibiotic-resistant pathogens has provided important insights into the distribution and prevalence of antibiotic resistance in Australia [40], and has highlighted rising rates of ESBL-producing and fluoroquinolone-resistant MDR causing BSIs [3, 7, 41]. Whole-genome sequencing (WGS) of pathogens causing BSIs facilitates the identification of AMR gene carriage and virulence-associated genes (VAGs) and links their carriage with ST, phylogroup and e-serotype. It also provides insights into the genetic context of AMR genes and VAGs and sheds light on the associations of AMR genes with mobile genetic elements. In addition to these attributes, WGS enables effective microbial source tracking. In this report, we present an analysis of whole-genome sequences collected from patients with bacteraemia (BSI) attending Concord Hospital, Sydney between January 2013 and March 2016. We investigate the genetic diversity of that cause BSIs, describe the genetic context of the resistance gene carried by these isolates and identify genetic elements that disseminate AMR genes and VAGs.

Methods

E. coli collection and growth conditions

Between January 2013 and March 2016, 406 isolates were collected by the Microbiology Department at Concord Repatriation Hospital in Sydney and stored as part of the Australian Group for Antimicrobial Resistance (AGAR) Gram-negative bacteraemia surveillance programme (GNSOP). We selected 81 isolates representative of the spectrum of phenotypic antibiotic resistance profiles for whole-genome sequence analysis. Clinical metadata, including collection year, likely source of infection and phenotypic resistance profile, are presented in File S1 (available in the online version of this article). A 48 h post-admission cut-off for sample collection was used to distinguish community-onset (CO) and hospital-onset (HO) infections. Isolates were sub-cultured and grown at 37 °C for 18 h on lysogeny broth (LB) and the pellets were used for purification of DNA.

Antimicrobial resistance phenotyping

Antibiotic susceptibility profiles were generated using the Advanced Expert System (AES) software designed for VITEK 2 (BioMerieux). Breakpoints were interpreted using European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [42] at the Microbiology Laboratory, Concord Hospital. The panel of antibiotics tested comprised ampicillin (AMP), amoxicillin (AMC), ciprofloxacin (CIP), cefazolin (CFZ), cefotaxime (CTX), ceftriaxone (CRO), ceftazidime (CAZ), cefoxitin (FOX), trimethoprim (TRI), gentamicin (GEN), tobramycin (TOB), norfloxacin (NOR), ticarcillin/clavulanic acid (TCC), piperacillin/tazobactam(TZP) trimethoprim/sulfamethoxazole (SXT) and amikacin (AMK). Synergy tests were used to phenotypically identify isolates producing ESBL enzymes (File S1). For the purposes of this study, multi-drug resistance was defined as resistance to ≥three classes of antibiotics [43].

Genomic DNA extraction and sequencing library preparation

Genomic DNA was extracted from 2 ml of overnight cultures using the ISOLATE II Genomic DNA kit (Bioline, Australia), following the manufacturer’s protocol, and quantified using the Qubit fluorimeter and dsDNA HS Assay kit (Thermo Fisher Scientific, Australia). WGS libraries were prepared from 2 ng of gDNA using the Illumina Nextera XT DNA kit following previously published protocols [44].

WGS and assembly

WGS was performed using the Illumina HiSeq 2500 v4 and the rapid PE150 mode (Illumina, San Diego, CA, USA). Based on FastQC reports, mean read lengths between 120 nt and 125 nt (with Phred scores ≥30) were used for genome assembly using the A5-miSeq pipeline (version 20150522) [45]. The number of scaffolds per genome varied from 30 to 200, with median sequence coverage ranging between 23× and 54× (File S2). Preliminary genome annotations were performed on RASTtk (http://rast.nmpdr.org/) [46] and regions of interest were manually curated using online versions of blastn and iterative blastp searches. The assembled genome sequences are available in GenBank under project ID PRJNA480723. The BioSample accession numbers are listed in File S2.

Gene identification and multi-locus sequence type (MLST) analysis

The Antimicrobial Resistance Identification By Assembly (ARIBA) pipeline (v2.6.1) [47] was used to rapidly detect the presence of the class 1 integrase gene intI1, antimicrobial resistance genes (ARGs), virulence-associated genes (VAGs), specific insertion elements, O- and H-antigen genes and Clermont phylogroups. The output was filtered strictly for hits that had 100 % query coverage and ≥99 % sequence identity. Genomes that did not return a match based on our stringent parameters were individually assessed either by blastn analysis (intI1 gene) or via portals on the Centre of Genomic Epidemiology website using assembled sequences (http://www.genomicepidemiology.org/) of respective genomes. Raw Illumina reads were mapped to pCERC-4 (accession no. KU578032) and pSDJ2009-52F (accession no. MH195200.1) to assess presence of genetic markers of the IncFII–IncFIB–ColV hybrid plasmids using published protocols [13]. The read mapping exercise was complemented with blast analysis of pCERC-4 against assembled genome sequences to present summary of findings presented in the manuscript. Genomes exhibiting ≥95 % sequence identity over 100 % query sequence of (i) a full complement of the colicin-V operon, (ii) virulence genes on pCERC-4 and (iii) linkage (defined by presence on the same genomic scaffold) of at least one of the repA genes on pCERC-4 with two or more Col-V-specific virulence gene/s, exhibiting specified identity cutoffs were identified as candidate genomes that likely host a Col-V plasmid. MLST analysis was performed using the Achtman MLST scheme on the PubMLST database (http://pubmlst.org/) and the plasmid replicons were identified using the Plasmid Finder database (https://cge.cbs.dtu.dk/services/PlasmidFinder/) [48].

Phylogenetic analysis

Reference gene-based maximum-likelihood phylogeny analysis (using 37 prokaryotic marker genes) was performed using Phylosift (v1.0.1) [49]. FastTree version 2.1.8 .c was used to construct a phylogenetic tree (http://www.microbesonline.org/fasttree/FastTree-2.1.8.c) and visualized using FigTree v1.4.2 [44]. The reference genomes used in the initial analysis were K12 (U00096.2) and EC958 (NZ_HG941718.1) and subsp. MGH78578 (CP000647.1) was used as an outlier. To increase the resolution of the branches, the outer layer was removed from the final tree presented in this paper (Figs 1 and 2). The tree figures were edited using iTol online tree management software (https://itol.embl.de/) and virulence heatmaps were created using the Burrows–Wheeler Aligner (BWA) 0.7.17, samtools 0.1.18 and ggplot2 in the R package [50] . The scripts and commands utilized for the heatmap are available on Github (https://github.com/maxlcummins/APEC-MGEN-2018). A mid-point rooted maximum-likelihood phylogenetic tree of isolates included in the cohort. Panels on the right-hand side indicate their year of isolation, in silico phylogrouping, O-antigen and H-antigen profiles. The tree includes two reference genomes, K12 and EC958. The year of isolation was not available for the two reference genomes and hence is labelled as NA NAin the metadata column. The strain labels coloured in blue indicate isolates from hospital-acquired infections. MDR strains are marked with an asterisk (*), ESBL producers are marked with a dollar sign ($) and fluoroquinolone-resistant isolates are marked with a hash (#). Diagrammatic representation of class 1 integron-associated complex resistance loci identified in this study. The terminal IS26s (red arrows) are mostly fragmented, and their relative orientation depicted in the diagram is based on analysis of the partial IS26 sequence. Figure not to scale.

Results

Isolate metadata

Clinical metadata corresponding to the 81 deidentified bacterial samples (File. S1) indicated that 37 isolates (45.5 %) were associated with UTIs and most of these (64/81; 79 %) were recovered from CO infections. The cohort included 35 MDR isolates of which 13 exhibited co-resistance to fluoroquinolones and ESBLs. Assembly statistics (File S2) indicated ≥23× coverage.

Phylogeny and ST distribution

Thirty different STs (File. S1) were identified within this BSI cohort. Phylogenetic analysis revealed two major ancestral clusters (Fig. 1). The upper major clade contained 25 isolates distributed in 16 STs (Fig. 1). Fifty-six isolates that clustered in the lower major clade comprised 15 STs, including globally recognized clonal groups ST73 (17 isolates), ST131 (15 isolates), ST95 (8 isolates) and ST127 (4 isolates). Isolates in the upper major clade of the phylogenetic tree contained representive of Clermont phylogroups B2, D, F, A and B1, while all isolates in the lower major clade of the phylogenetic tree, irrespective of ST type and O and H surface antigens typed as phylogroup B2, known to be associated with pathogenic strains. The relative abundance of CO infections within clinically significant STs were ST73 (16 of 17), ST131 (10 of 15), ST95 (7 of 8) and ST69 (2 of 5) was noteworthy. The resistance genes, class 1 integron-associated genes and plasmid replicon types in the entire cohort are presented in Table 1.
Fig. 1.

A mid-point rooted maximum-likelihood phylogenetic tree of isolates included in the cohort. Panels on the right-hand side indicate their year of isolation, in silico phylogrouping, O-antigen and H-antigen profiles. The tree includes two reference genomes, K12 and EC958. The year of isolation was not available for the two reference genomes and hence is labelled as NA NAin the metadata column. The strain labels coloured in blue indicate isolates from hospital-acquired infections. MDR strains are marked with an asterisk (*), ESBL producers are marked with a dollar sign ($) and fluoroquinolone-resistant isolates are marked with a hash (#).

Table 1.

Resistance genes and plasmid profile of isolates sequenced and analysed in this study.

Isolate descriptor

Resistance genes in the genome

Class 1 integron-associated genes

ESBL genes

Fluoroquinolone resistance genes

Plasmid replicons

EC70_ST131H * $ #

aac-3-lla, aacA4, aadA5, dfrA17, sul1, TEM-1B

aadA5, dfrA17,mph(A), sul1

CTX-M-15, OXA-1

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII

EC137_ST2003C * $ #

aac-3-Ib, aac(6')−1b-cr, aacA4,cmlA1, dfrA1, mph(A), sul1, tet(B), TEM-1B

aacA4,cmlA1

CTX-M-14

gyrA(S83L, D87N);parC(S80I), aac(6')−1b-cr

IncFII, IncFIB, IncFIA, Col156,pColBS512

EC234_ST8196H * $ #

qnrB4, aac-3-lla, aadA5, dfrA17, mph(A), sul1, blaDHA-1

aadA5, dfrA17,sul1,mph(A)

CTX-M-15

gyrA(S83L, D87N);parC(S80I, E84V),qnrB4

IncFII, IncI1, Col156, pColBS512

EC345_ST10C * #

aadA1, catA1, tet(B)

OXA1, aadA1

OXA-1

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII

EC385_ST73C *

aph-3-Ia, TEM-1B, dfrA17, mph(A), strA/B, sul2, tet(B)

dfrA17

gyrA(S83L)

IncFII, IncFIB, Col156, pColBS512

EC308_ST131C *

catA1, dfrA7, sul1, TEM-1B

catA1, dfrA7

IncFII, IncFIA, IncFIB, Col156

EC236_ST540C * #

aph-3-la, dfrA5, sul1, sul2, strA/B tet(A), TEM-1B

dfrA5

IncFII, IncFIB, pBS512,pSL483

EC247_ST69H *

dfrA7, sul1, sul2, strA/B, tet(A), TEM-1B

dfrA7

IncFII, IncFIA, IncFIB, pCol4401

EC275_ST131C *

aac-3-lld,aadA5, dfrA17, mph(A), sul1, sul2, strA/B, tet(A), TEM-1B

aadA5, dfrA17,sul1,mph(A)

gyrA(S83L)

IncFII, IncFIB, Col156

EC398_ST4702C * $

aac-3-lld, aadA5, dfrA17, mph(A), sul1,TEM-1B

aadA5, dfrA17,sul1,mph(A)

CTX-M-14

IncFII, IncFIB, IncFIA, Col156,pColBS512

EC297_ST131C * $ #

aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A)

aadA5, dfrA17,mph(A), sul1, strA/B, sul2

CTX-M-27

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII, IncFIB, IncFIA,IncB,

EC357_ST131C * $ #

aac-3-IIb, aacA4, dfrA14, strA/B, sul2, tet(A), TEM-1B

dfrA14

CTX-M-15, OXA-1

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII, IncFIB

EC231_ST38C * $

aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A)

aadA5, dfrA17,mph(A), sul1, strA/B, sul2

CTX-M-27

IncFII, IncFIB

EC46_ST131H * $ #

aac-3-lla, aac(6')−1b-cr, aadA5, dfrA17, mph(A), sul1, sul2, strA, floR, TEM-1C

aadA5, dfrA17,mph(A), sul1, strA/B, sul2

CTX-M-15, OXA-1

gyrA(S83L, D87N);parC(S80I, E84V), aac(6')−1b-cr

IncFII, IncFIB, IncFIA, IncX4, Col156

EC36_ST38H * $ #

aac-3-lld, aadA5, dfrA17, mph(A), sul1, sul2, strA/B, tet(A), TEM-1B

aadA5, dfrA17,mph(A), sul1, strA/B, sul2

CTX-M-15

gyrA(S83L, D87N);parC(S80I)

IncFII, IncFIB, IncI1, Col156

EC169_ST73C * #

aadA1, sul1, TEM-1B

aadA1,sul1

IncFII, IncFIB, Col156

EC12_ST131H * #

aadA5, dfrA17, mph(A), sul1, TEM-1B

aadA5, dfrA17,sul1,mph(A)

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII, IncFIA, IncI1, Col156

EC222_ST73H *

aadA1, sul1, TEM-1B

aadA1

IncFII, IncFIB, Col156

EC182_ST73C *

aadA1, dfrA1, sul1, strA/B, sul2, TEM-1B

aadA1, dfrA1

IncFII, IncFIB, IncFIA

EC149_ST73C *

aadA1, dfrA14,strA/B,sul2,sul1, TEM-1B

aadA1, dfrA14

IncFII, IncFIB, Col156

EC8_ST131C *

aadA5, dfrA17, mph(A), sul1, TEM-1B

aadA5, dfrA17

IncFII, IncFIB, IncFIA, IncX4, Col156

EC233_ST8196C * $ #

qnrB4, aac-3-lla, aadA5, dfrA17, mph(A), sul1, blaDHA-1

aadA5, dfrA17,sul1,mph(A)

CTX-M-15

gyrA(S83L, D87N);parC(S80I, E84V), qnrB4

IncFII, IncI1, Col156, pColBS512

EC120_ST131C * $ #

aac-3-Ib, aacA4, dfrA14, strA/B, sul2, TEM-1B

dfrA14

CTX-M-15, OXA-1

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII, IncFIB, IncFIA, IncI, pCol440II

EC44_ST131H * $ #

aac-3-lla, aac(6')−1b-cr, aadA5, dfrA17, mph(A), sul1, sul2, strA, floR, TEM-1C

aadA5, dfrA17,mph(A), sul1, strA/B, sul2

CTX-M-15, OXA-1

gyrA(S83L, D87N);parC(S80I, E84V), parE(I529L), aac(6′)−1b-cr

IncFII, IncFIB, IncFIA, IncX4, Col156

EC66_ST393C * $ #

aadA5, dfrA17, mph(A), sul1, ermB

aadA5, dfrA17,sul1,mph(A)

CTX-M-15

gyrA(S83L, D87N);parC(S57T,S80I), parE (L416F)

IncFIB, IncFIA, Col156

EC87_ST131C * $ #

aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A)

aadA5, dfrA17,mph(A), sul1, strA/B, sul2

CTX-M-27

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII, IncFIA, pColBS512

EC164_ST73C *

TEM-1B

0

EC226_ST349C *

0

EC285_ST648C * #

gyrA(S83L, D87N);parC(S80I)

0

EC274_ST38H * #

aac-3-lld, catA1, tet(B), TEM-1B

gyrA(S83L, D87N);parC(S80I, E84G)

IncFII, IncFIB

EC282_ST73C *

TEM-1B

IncFII

EC179_ST131C * $ #

CTX-M-27

gyrA(S83L, D87N);parC(S80I, E84V)

IncFII, IncFIB, IncFIA, IncB, Col156

EC168_ST73C *

TEM-1B

IncFII, IncFIB, IncX4, Col156

EC25_ST88H *

aadA1, dfrA1, sul1, TEM-1B

aadA1, dfrA1

0

EC393_ST131C * #

TEM-1B

gyrA(S83L)

0

EC302_ST349C

dfrA17, sul1, sul2, strA/B, tet(A), TEM-1B

dfrA17

IncFII, IncQ

EC272_ST73C

aadA1, sul1, TEM-1B

aadA1

IncFII, IncFIB, Col156

EC347_ST73C

aadA1, sul1

aadA1

SHV-48

IncFII, IncFIB, Col156

EC337_ST69H

dfrA5, TEM-1B

dfrA5

IncB, IncFIB

EC323_ST549H

dfrA5, TEM-1B

dfrA5

IncFII, IncFIB

EC330_ST681C

dfrA5, sul1, strA/B, sul2, tet(A), TEM-1B

dfrA5

IncB, ColBS512

EC290_ST127C

dfrA5, sul1, TEM-1B

dfrA5

IncFIB, Col156

EC273_ST1434C

aph-3-la, dfrA5, sul2, strA/B tet(A), TEM-1B

dfrA5

IncFII, IncFIB, IncHI1, IncX4

EC131_ST131C

aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A)

aadA5, dfrA17

gyrA(S83L)

IncFII, IncFIB, Col156

EC239_ST62C

catA1, dfrA17

dfrA17

IncFII, IncFIB,Col156

EC147_ST73C

aadA1,dfrA1, strA/B, sul1, sul2, TEM-1B

aadA1, dfrA1

IncFII, IncFIB, IncI1, Col156

EC65_ST127C

aadA1, sul1, TEM-1B

aadA1

IncFII, IncFIB, Col156

EC173_ST12C

aadA1, dfrA1, sul1, tet(B), TEM-1B

aadA1, dfrA1

IncFIA, IncFIB, Col156, ColVC

EC108_95C

aadA2, catA1, dfrA12, mph(A), sul1, tet(B), TEM-1B

dfrA12, aadA2

IncFII, IncFIB, IncFIA, Col156

EC16_ST1193C #

dfrA17, strA/B, sul2, tet(B), TEM-1B

dfrA17

gyrA(S83L, D87N);parC(S80I)

IncFII, IncFIB, IncFIA, IncQ, Col156

EC5_ST73C

aadA1, sul1, TEM-1B

aadA1

IncFII, IncFIB, Col156

EC152_ST95C

aadA1, aadA2, cmlA1, dfrA12, sul3

aadA1, orfF, aadA2, cmlA1, dfrA12, sul3

IncFII, IncFIB

EC177_ST95H

dfrA5

dfrA5

IncFII, IncFIB, Col156

EC45_ST57C

aadA1, dfrA5, sul1, sul2, tet(C)

aadA1, dfrA5

IncFII, IncFIB

EC84_ST131H

dfrA14, mphA

dfrA14

IncFII, IncFIB, Col156

EC56_ST164C

0

EC2_ST95C

IncFIA, IncFIB, Col156

EC160_ST73C

IncFII, IncFIB, Col156

EC178_ST69C

TEM-1B

gyrA(S83L)

IncFII, IncFIB, IncFIA

EC250_ST127C

0

EC235_ST117C

IncFIB

EC230_ST91C

IncFII, IncFIB

EC280_ST144C

TEM-1B

OXA-4

IncFII, IncFIB, Col156

EC232_ST73C

0

EC249a_ST127H

IncFII, IncFIB

EC276_ST906C

IncFII, IncFIB

EC33_ST73C

TEM-1B, sul2

0

EC7_ST144C

dfrA14, sul2, strA/B, TEM-1B

IncB, IncFII, IncFIB, Col156

EC11_ST95C

TEM-1B

IncFII, IncFIB

EC51_ST69C

sul1, TEM-1B

IncB, IncFII, IncFIB, Col156

EC128_ST8197H

TEM-1C

IncFII, IncFIB, IncB, Col156

EC15_ST5242C

0

EC19_ST372C

0

EC35_ST69H

IncB, IncFII, IncFIB, Col156

EC68_ST95C

tet(B)

IncFIA, IncFII, IncFIB

EC20_ST73C

0

EC372_ST95C

IncFIA, IncFIB, Col156

EC104_ST95C

strA, strB, tet(B)

gyrA(S83L)

IncFII, IncFIB

EC123_ST88C

strA, strB, sul2

IncFII, IncFIB, IncQ

EC24_ST73C

0

EC223_ST62C

aadA1, dfrA1, tet(A)

gyrA(S83L)

IncFIB, Col156

The isolate descriptor column consists of isolate number, the sequence type (ST) and hospital onset (H) or community onset (C) included as suffix, followed by symbols to include phenotypic profile, where MDR is indicated as *, ESBL producers are indicated as $ and fluoroquinolone -resistant isolates indicated as #.

Resistance genes and plasmid profile of isolates sequenced and analysed in this study. Isolate descriptor Resistance genes in the genome Class 1 integron-associated genes ESBL genes Fluoroquinolone resistance genes Plasmid replicons EC70_ST131H * $ # aac-3-lla, aacA4, aadA5, dfrA17, sul1, TEM-1B aadA5, dfrA17,mph(A), sul1 CTX-M-15, OXA-1 gyrA(S83L, D87N);parC(S80I, E84V) IncFII EC137_ST2003C * $ # aac-3-Ib, aac(6')−1b-cr, aacA4,cmlA1, dfrA1, mph(A), sul1, tet(B), TEM-1B aacA4,cmlA1 CTX-M-14 gyrA(S83L, D87N);parC(S80I), aac(6')−1b-cr IncFII, IncFIB, IncFIA, Col156,pColBS512 EC234_ST8196H * $ # qnrB4, aac-3-lla, aadA5, dfrA17, mph(A), sul1, blaDHA-1 aadA5, dfrA17,sul1,mph(A) CTX-M-15 gyrA(S83L, D87N);parC(S80I, E84V),qnrB4 IncFII, IncI1, Col156, pColBS512 EC345_ST10C * # aadA1, catA1, tet(B) OXA1, aadA1 OXA-1 gyrA(S83L, D87N);parC(S80I, E84V) IncFII EC385_ST73C * aph-3-Ia, TEM-1B, dfrA17, mph(A), strA/B, sul2, tet(B) dfrA17 gyrA(S83L) IncFII, IncFIB, Col156, pColBS512 EC308_ST131C * catA1, dfrA7, sul1, TEM-1B catA1, dfrA7 IncFII, IncFIA, IncFIB, Col156 EC236_ST540C * # aph-3-la, dfrA5, sul1, sul2, strA/B tet(A), TEM-1B dfrA5 IncFII, IncFIB, pBS512,pSL483 EC247_ST69H * dfrA7, sul1, sul2, strA/B, tet(A), TEM-1B dfrA7 IncFII, IncFIA, IncFIB, pCol4401 EC275_ST131C * aac-3-lld,aadA5, dfrA17, mph(A), sul1, sul2, strA/B, tet(A), TEM-1B aadA5, dfrA17,sul1,mph(A) gyrA(S83L) IncFII, IncFIB, Col156 EC398_ST4702C * $ aac-3-lld, aadA5, dfrA17, mph(A), sul1,TEM-1B aadA5, dfrA17,sul1,mph(A) CTX-M-14 IncFII, IncFIB, IncFIA, Col156,pColBS512 EC297_ST131C * $ # aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A) aadA5, dfrA17,mph(A), sul1, strA/B, sul2 CTX-M-27 gyrA(S83L, D87N);parC(S80I, E84V) IncFII, IncFIB, IncFIA,IncB, EC357_ST131C * $ # aac-3-IIb, aacA4, dfrA14, strA/B, sul2, tet(A), TEM-1B dfrA14 CTX-M-15, OXA-1 gyrA(S83L, D87N);parC(S80I, E84V) IncFII, IncFIB EC231_ST38C * $ aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A) aadA5, dfrA17,mph(A), sul1, strA/B, sul2 CTX-M-27 IncFII, IncFIB EC46_ST131H * $ # aac-3-lla, aac(6')−1b-cr, aadA5, dfrA17, mph(A), sul1, sul2, strA, floR, TEM-1C aadA5, dfrA17,mph(A), sul1, strA/B, sul2 CTX-M-15, OXA-1 gyrA(S83L, D87N);parC(S80I, E84V), aac(6')−1b-cr IncFII, IncFIB, IncFIA, IncX4, Col156 EC36_ST38H * $ # aac-3-lld, aadA5, dfrA17, mph(A), sul1, sul2, strA/B, tet(A), TEM-1B aadA5, dfrA17,mph(A), sul1, strA/B, sul2 CTX-M-15 gyrA(S83L, D87N);parC(S80I) IncFII, IncFIB, IncI1, Col156 EC169_ST73C * # aadA1, sul1, TEM-1B aadA1,sul1 IncFII, IncFIB, Col156 EC12_ST131H * # aadA5, dfrA17, mph(A), sul1, TEM-1B aadA5, dfrA17,sul1,mph(A) gyrA(S83L, D87N);parC(S80I, E84V) IncFII, IncFIA, IncI1, Col156 EC222_ST73H * aadA1, sul1, TEM-1B aadA1 IncFII, IncFIB, Col156 EC182_ST73C * aadA1, dfrA1, sul1, strA/B, sul2, TEM-1B aadA1, dfrA1 IncFII, IncFIB, IncFIA EC149_ST73C * aadA1, dfrA14,strA/B,sul2,sul1, TEM-1B aadA1, dfrA14 IncFII, IncFIB, Col156 EC8_ST131C * aadA5, dfrA17, mph(A), sul1, TEM-1B aadA5, dfrA17 IncFII, IncFIB, IncFIA, IncX4, Col156 EC233_ST8196C * $ # qnrB4, aac-3-lla, aadA5, dfrA17, mph(A), sul1, blaDHA-1 aadA5, dfrA17,sul1,mph(A) CTX-M-15 gyrA(S83L, D87N);parC(S80I, E84V), qnrB4 IncFII, IncI1, Col156, pColBS512 EC120_ST131C * $ # aac-3-Ib, aacA4, dfrA14, strA/B, sul2, TEM-1B dfrA14 CTX-M-15, OXA-1 gyrA(S83L, D87N);parC(S80I, E84V) IncFII, IncFIB, IncFIA, IncI, pCol440II EC44_ST131H * $ # aac-3-lla, aac(6')−1b-cr, aadA5, dfrA17, mph(A), sul1, sul2, strA, floR, TEM-1C aadA5, dfrA17,mph(A), sul1, strA/B, sul2 CTX-M-15, OXA-1 gyrA(S83L, D87N);parC(S80I, E84V), parE(I529L), aac(6′)−1b-cr IncFII, IncFIB, IncFIA, IncX4, Col156 EC66_ST393C * $ # aadA5, dfrA17, mph(A), sul1, ermB aadA5, dfrA17,sul1,mph(A) CTX-M-15 gyrA(S83L, D87N);parC(S57T,S80I), parE (L416F) IncFIB, IncFIA, Col156 EC87_ST131C * $ # aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A) aadA5, dfrA17,mph(A), sul1, strA/B, sul2 CTX-M-27 gyrA(S83L, D87N);parC(S80I, E84V) IncFII, IncFIA, pColBS512 EC164_ST73C * TEM-1B 0 EC226_ST349C * 0 EC285_ST648C * # gyrA(S83L, D87N);parC(S80I) 0 EC274_ST38H * # aac-3-lld, catA1, tet(B), TEM-1B gyrA(S83L, D87N);parC(S80I, E84G) IncFII, IncFIB EC282_ST73C * TEM-1B IncFII EC179_ST131C * $ # CTX-M-27 gyrA(S83L, D87N);parC(S80I, E84V) IncFII, IncFIB, IncFIA, IncB, Col156 EC168_ST73C * TEM-1B IncFII, IncFIB, IncX4, Col156 EC25_ST88H * aadA1, dfrA1, sul1, TEM-1B aadA1, dfrA1 0 EC393_ST131C * # TEM-1B gyrA(S83L) 0 EC302_ST349C dfrA17, sul1, sul2, strA/B, tet(A), TEM-1B dfrA17 IncFII, IncQ EC272_ST73C aadA1, sul1, TEM-1B aadA1 IncFII, IncFIB, Col156 EC347_ST73C aadA1, sul1 aadA1 SHV-48 IncFII, IncFIB, Col156 EC337_ST69H dfrA5, TEM-1B dfrA5 IncB, IncFIB EC323_ST549H dfrA5, TEM-1B dfrA5 IncFII, IncFIB EC330_ST681C dfrA5, sul1, strA/B, sul2, tet(A), TEM-1B dfrA5 IncB, ColBS512 EC290_ST127C dfrA5, sul1, TEM-1B dfrA5 IncFIB, Col156 EC273_ST1434C aph-3-la, dfrA5, sul2, strA/B tet(A), TEM-1B dfrA5 IncFII, IncFIB, IncHI1, IncX4 EC131_ST131C aadA5, dfrA17, mph(A), sul1, strA/B, sul2, tet(A) aadA5, dfrA17 gyrA(S83L) IncFII, IncFIB, Col156 EC239_ST62C catA1, dfrA17 dfrA17 IncFII, IncFIB,Col156 EC147_ST73C aadA1,dfrA1, strA/B, sul1, sul2, TEM-1B aadA1, dfrA1 IncFII, IncFIB, IncI1, Col156 EC65_ST127C aadA1, sul1, TEM-1B aadA1 IncFII, IncFIB, Col156 EC173_ST12C aadA1, dfrA1, sul1, tet(B), TEM-1B aadA1, dfrA1 IncFIA, IncFIB, Col156, ColVC EC108_95C aadA2, catA1, dfrA12, mph(A), sul1, tet(B), TEM-1B dfrA12, aadA2 IncFII, IncFIB, IncFIA, Col156 EC16_ST1193C # dfrA17, strA/B, sul2, tet(B), TEM-1B dfrA17 gyrA(S83L, D87N);parC(S80I) IncFII, IncFIB, IncFIA, IncQ, Col156 EC5_ST73C aadA1, sul1, TEM-1B aadA1 IncFII, IncFIB, Col156 EC152_ST95C aadA1, aadA2, cmlA1, dfrA12, sul3 aadA1, orfF, aadA2, cmlA1, dfrA12, sul3 IncFII, IncFIB EC177_ST95H dfrA5 dfrA5 IncFII, IncFIB, Col156 EC45_ST57C aadA1, dfrA5, sul1, sul2, tet(C) aadA1, dfrA5 IncFII, IncFIB EC84_ST131H dfrA14, mphA dfrA14 IncFII, IncFIB, Col156 EC56_ST164C 0 EC2_ST95C IncFIA, IncFIB, Col156 EC160_ST73C IncFII, IncFIB, Col156 EC178_ST69C TEM-1B gyrA(S83L) IncFII, IncFIB, IncFIA EC250_ST127C 0 EC235_ST117C IncFIB EC230_ST91C IncFII, IncFIB EC280_ST144C TEM-1B OXA-4 IncFII, IncFIB, Col156 EC232_ST73C 0 EC249a_ST127H IncFII, IncFIB EC276_ST906C IncFII, IncFIB EC33_ST73C TEM-1B, sul2 0 EC7_ST144C dfrA14, sul2, strA/B, TEM-1B IncB, IncFII, IncFIB, Col156 EC11_ST95C TEM-1B IncFII, IncFIB EC51_ST69C sul1, TEM-1B IncB, IncFII, IncFIB, Col156 EC128_ST8197H TEM-1C IncFII, IncFIB, IncB, Col156 EC15_ST5242C 0 EC19_ST372C 0 EC35_ST69H IncB, IncFII, IncFIB, Col156 EC68_ST95C tet(B) IncFIA, IncFII, IncFIB EC20_ST73C 0 EC372_ST95C IncFIA, IncFIB, Col156 EC104_ST95C strA, strB, tet(B) gyrA(S83L) IncFII, IncFIB EC123_ST88C strA, strB, sul2 IncFII, IncFIB, IncQ EC24_ST73C 0 EC223_ST62C aadA1, dfrA1, tet(A) gyrA(S83L) IncFIB, Col156 The isolate descriptor column consists of isolate number, the sequence type (ST) and hospital onset (H) or community onset (C) included as suffix, followed by symbols to include phenotypic profile, where MDR is indicated as *, ESBL producers are indicated as $ and fluoroquinolone -resistant isolates indicated as #. STs ST8196 (two isolates) and ST8197 (one isolate) are novel and were registered in Enterobase (https://enterobase.warwick.ac.uk/species/index/ecoli). ST8196 is closely related to the ST131-O25:H4 sub-clade (Fig. 1) and is a new member of the ST131 clonal complex. The ST8196 isolates, EC233 and EC234, were MDR and were isolated from blood specimens of separate patients within a 24 h period. EC233 was from a patient with CO UTI, while EC234 was from a patient with a hospital-onset infection. Both isolates displayed phenotypic resistance to fluoroquinolones and produced ESBLs. The ST8197 isolate EC128 is closely related to members of the ST144 subclade (Fig. 1), a ST that shares the closest common ancestor with ST95. Isolate EC128_ST8197 was resistant to ampicillin and trimethoprim/sulfamethoxazole and susceptible to all other antibiotics tested. Most (21; 60 %) of the 35 MDR isolates clustered within the ST131 (13 isolates) and ST73 (8 isolates) subclades (Fig. 1). Genes responsible for ESBL production and fluoroquinolone resistance phenotypes in the MDR -cohort were not restricted to isolates in the ST131 sub-clade, but also present in ST38 (HO isolate EC36), ST393 (CO isolate EC66), ST2003 (CO isolate EC137) and ST8196 (EC233 from CO and EC234 from HO) representatives.

Genetic context of class 1 integrons and resistance genes

Of the 81 isolates, 47 (58 %) carried a class 1 integron (Table 1). Aminoglycoside adenyl transferase genes aadA1, aadA2 (streptomycin resistance) and aadA5 (spectinomycin resistance), dihydrofolate reductase gene alleles dfrA1, dfrA7, dfrA14, dfrA14 and dfrA17, encoding resistance to trimethoprim, cmlA1 (encoding chloramphenicol resistance) and bla OXA-1 (encoding host-specific low-level resistance to ESBL antibiotics), were most frequently present in cassette arrays associated with class 1 integrons in this collection (Table 1). The IncX4 replicon was identified in five isolates. Sixteen isolates harboured the aadA5–dfrA17 [Fig. 2a (14), e(2)] cassette array, while others comprised different combinations of the gene cassettes listed above and in Table 1. Genomic scaffolds containing class 1 integrons often carried other clustered resistance genes (Fig. 2) interspersed with different insertion elements. Integrons bearing the aadA5–dfrA17 cassette array were almost always linked to a macrolide resistance module encoded by mphA and mphR genes beyond the 3′-CS (conserved segment) of the class 1 integron, forming a complex resistance locus (CRL) (Fig. 2a). IS26 sequences flanked the majority of scaffolds carrying a class 1 integron (Fig. 2). Most isolates (64/81; 79 %), irrespective of the resistance gene carriage, carried multiple copies of IS26 (File S1), which likely contributed to fragmentations in genome assemblies.
Fig. 2.

Diagrammatic representation of class 1 integron-associated complex resistance loci identified in this study. The terminal IS26s (red arrows) are mostly fragmented, and their relative orientation depicted in the diagram is based on analysis of the partial IS26 sequence. Figure not to scale.

The genes encoding resistance to ESBL were restricted to three allelic variants of bla CTX-M: bla CTX-M-14, bla CTX-M-15 and bla CTX-M-27. In most instances, bla CTX-M-15 genes were associated with ISEcp1 (File S1). In EC137_ST2003 and EC398_ST4702, bla CTX-M-14 was associated with ISEcp1b. Isolate EC345_ST10 had a class 1 integron with a bla OXA-1 gene cassette (Fig. 2i), but with no detectable enzymatic activity. Fluoroquinolone resistance in most isolates was attributed to mutations in gyrB and parC chromosomal genes except in isolates EC46_ST131, EC44_ST131 and EC137_ST2003, which additionally had acquired aac(6′)−1b-cr, a gene known to confer low-level resistance to fluoroquinolones and aminoglycosides. Fluoroquinolone resistance gene qnrB4 was identified in isolates EC233_ST8196 and EC234_ST8196.

phylogroups and virulence gene profiling

Eighty-one genomes were screened against a panel of 65 VAGs commonly found in pathogenic (Fig. 3, Files S3 and S4). The relative abundance of VAGs was highest in ST95 and ST73 isolates, followed by ST131 (Fig. 3, File. S4). In congruence with recent reports on co-relation between phylogroups and virulence gene profiles [51, 52], isolates belonging to Clermont phylogroups A, B1 and F carried fewer VAGs than the isolates in phylogroups B2 and D (File S4). The fimH, yeeT, fyuA, irp2, sitA and iss genes were identified in over 80 % of the isolates in our cohort (File S3). Only four isolates, EC104, EC2, EC230 and EC19 (all phylogroup B2), carried ibeA. Of the 2 iron acquisition genes, iucD and irp2, iucD was present in 52 isolates (8 phylogroup D and 1 each of phylogroups A and D, with the rest B2), and 72 tested positive for irp2 (all 68 phylogroup B2 and 2 each of A and F). A previous single hospital study of from BSIs also highlighted an abundance of fimH, papC, iha and ibeA genes [53].
Fig. 3.

A presence/absence heatmap of virulence genes. The phylogenetic relationship of the isolates is presented as a cladogram along the y-axis and the virulence genes are listed in the top panel along the x-axis. Grey boxes indicate the presence and black boxes indicate the absence of a gene. Virulence gene profiling was not performed for the two reference genomes (EC958 and K12), hence the corresponding rows are left blank.

A presence/absence heatmap of virulence genes. The phylogenetic relationship of the isolates is presented as a cladogram along the y-axis and the virulence genes are listed in the top panel along the x-axis. Grey boxes indicate the presence and black boxes indicate the absence of a gene. Virulence gene profiling was not performed for the two reference genomes (EC958 and K12), hence the corresponding rows are left blank. The distribution of the six ExPEC-specific protectins, namely kpsMT II, kpsMT III, traT, ompT, iss and cavC, and two toxins, hly and cnf1, was also determined. Forty isolates tested positive for kpsMT II, while only isolate EC323 tested positive for kpsMT III. Fourteen isolates were positive for ompT, 58 for traT, 67 for iss and 11 for cavC (File S3). None of the isolates tested positive for hlyA, but 22 (all phylogroup B2) were positive for cnf1. No obvious trend was observed in the relative distribution of genes encoding known outer-membrane iron receptors, such as fyuA, ireA, iroN and iutA, amongst the different sequence types, phylogroups (File S4) or CO vs HO infections.

Plasmid replicon diversity within the cohort

Plasmid typing identified IncFII and IncFIB replicons in most isolates (51/81), including 39 CO BSI and 12 HO BSI isolates (Table 1). In 11 isolates from CO infections and 3 from HO infections, FIA replicons were co-resident with IncFII and IncFIB replicons. We also identified small col-like plasmid replicons in 33 of the 51 isolates that carried IncFII and IncFIB replicons, raising the possibility of presence of large IncFII–IncFIB hybrid ColV-like virulence plasmids in them. Two completely closed IncFII–IncFIB hybrid ColV-like plasmids, pCERC4 (Fig. S1a) and pSDJ2009-52F (Fig. S1b), have recently been reported and characterized [54, 55] from Sydney. Illumina read mapping of all 81 genomes against both plasmids identified 12 isolates which appeared to carry most of the virulence and colicin resistance genes characteristic of ColV hybrid virulence plasmids (Fig. S1a, b). To examine this further, a series of blastn analyses of the ColV operon, col-Ia genes, the virulence gene repertoire and their linkage to repA and repA1 genes found on pCREC4 was conducted against all assembled genomes in our cohort. Combining data on scaffolds identified in our blastn analyses (File S5) and following the stringent parameters indicated in the Methods section, our assessment identified genetic features that define ColV-like IncFII–IncFIB plasmids in 10 isolates (Table 2). Of these, five typed as ST95 (EC104, EC68, EC177, EC152, EC11), two each as ST131 (EC120 and EC357) and ST88 (EC25, EC123), and one as ST540 (EC236). Two genomes (EC337 and EC323) that had the Col-V operon and col-Ia genes did not contain both (IncFII and IncFIB) replicons characteristic of hybrid IncFII–IncFIB plasmids and likely represent isolates with novel ColV-like IncF plasmid variants. All 10 isolates identified in the analysis as candidates likely hosting IncFII–IncFIB ColV-like plasmids did not return positive hits for both ColV operon and col-Ia genes (Table 2), indicating subtle variations in the structure of plasmids in this group. Further studies with completely closed plasmid sequences are required to characterize them and examine the distribution of all ColV-like plasmid variants within isolates from the clinic and elsewhere.
Table 2.

Summary of the blastn analysis of genomes with col V operon, col-Ia genes and the repertoire of virulence genes and the repA gene present on pCERC-4 (accession no. KU578032).

Isolate identifier

Sequence type

pCREC-4 rep genes

Positive hits to pCERC-4 virulence gene (n=20)

Isolates with both colV operon and col-Iagenes

  EC337_ST69H

69

repA_FIB

iroC,iutA,iroN,etsB,iucA,iucC,etsC,iucD,iroD,etsA,iroB,hlyF,iroE,ompT,iucB,sitA,sitD,sitC,sitB,iss

  EC25_ST88H*

88

repA_FIB, repA1_FII

iroC,iutA,iroN,etsA, etsB,etsC, iucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitA,sitD,sitC,sitB,iss

  EC104_ST95C*

95

repA_FIB, repA1_FII$

iroC ,iutA,iroN,etsA, etsB,etsCiucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitC,sitB,sitA,sitD,iss

  EC68_ST95C*

95

repA_FIB, repA1_FII$

iroC,iutA,iroN,etsA, etsB,etsCiucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitC,sitD,sitB,sitA,iss

  EC177_ST95H*

95

repA_FIB, repA1_FII

iroC,iroN,etsA,etsB,etsC,iroD, iroB,hlyF,iroE,ompT,sitA,sitC,sitD,sitB,iss

  EC120_ST131C*

131

repA_FIB, repA1_FII$

iroC,iutA,iroN,etsA, etsB,etsC,iucA,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitC,sitB,iucC,sitA,sitD,iss

  EC236_ST540C*

540

repA_FIB, repA1_FII

iroC,iutA,iroN,etsB,iucA,iucC,etsC,iucD,iroD,etsA,iroB,hlyF,iroE,ompT,iucB,sitA,sitD,sitC,sitB,iss

  EC323_ST549H*

549

repA_FIB

iroC ,iutA,iroN,etsA, etsB,etsC,iucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitA,sitD,sitC,sitB,iss

Isolates with colV operon only

  EC123_ST88C*

88

repA_FIB, repA1_FII$

iroC,iutA,iroN,etsA, etsB,etsC,iucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitA,sitD,sitC,sitB,iss

  EC152_ST95C*

95

repA_FIB, repA1_FII$

iroC,iutA,iroN,etsA, etsB,etsC,iucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitC,sitB,sitD,sitA,iss

  EC11_ST95C*

95

repA_FIB, repA1_FII$

iroC,iutA,iroN,etsA, etsB,etsC,iucA,iucC,iucD,iroD,iroB,hlyF,iroE,ompT,iucB,sitC,sitB,sitA,sitD,iss

  EC357_ST131C*

131

repA_FIB, repA1_FII$

iroC,iutA,iroN,etsA, etsB,etsC,iucA,iucD,iroD,iroB,hlyF,iucC,iroE,ompT,iucB,sitC,sitB,sitA

Isolates with col-Iagenes only

  EC232_ST73C

73

None detected

iroC,iutA,iroN,iucA,iucC,iucD,iroD,iroB,iroE,iucB,sitA,sitC,sitD,sitB,iss

  EC230_ST91C

91

repA_FIB$, repA1_FII$

sitA,sitC,sitD,sitB,iss

  EC12_ST131H

131

repA1_FII$

iutA,iucA,iucC,iucD,iucB,sitA,sitC,sitD,sitB,iss

Asterisk (*) on ‘isolate identifiers’ indicates linkage of repA with virulence genes on the same genomic scaffold (detailed in File S5). Virulence genes highlighted in bold fonts indicate genes that were assembled on a single scaffold with the repA gene, indicating linkage. A dollar ($) sign in the pCERC-4 rep gene column represents ≥95 % but not 100 % identity with the respective rep gene sequence.

Summary of the blastn analysis of genomes with col V operon, col-Ia genes and the repertoire of virulence genes and the repA gene present on pCERC-4 (accession no. KU578032). Isolate identifier Sequence type pCREC-4 rep genes Positive hits to pCERC-4 virulence gene (n=20) EC337_ST69H 69 repA_FIB iroC,iutA,iroN,etsB,iucA,iucC,etsC,iucD,iroD,etsA,iroB,hlyF,iroE,ompT,iucB,sitA,sitD,sitC,sitB,iss EC25_ST88H* 88 repA_FIB, repA1_FII iroC,iutA,iroN, EC104_ST95C* 95 repA_FIB, repA1_FII ,iutA, EC68_ST95C* 95 repA_FIB, repA1_FII iroC,iutA,iroN, EC177_ST95H* 95 repA_FIB, repA1_FII iroC,iroN,etsA,etsB,etsC,iroD, iroB, EC120_ST131C* 131 repA_FIB, repA1_FII iroC,iutA,iroN, EC236_ST540C* 540 repA_FIB, repA1_FII iroC,iutA,iroN,etsB,iucA,iucC,etsC,iucD,iroD,etsA,iroB, EC323_ST549H* 549 repA_FIB ,iutA, EC123_ST88C* 88 repA_FIB, repA1_FII iroC,iutA,iroN, EC152_ST95C* 95 repA_FIB, repA1_FII iroC,iutA,iroN, EC11_ST95C* 95 repA_FIB, repA1_FII iroC,iutA,iroN, EC357_ST131C* 131 repA_FIB, repA1_FII iroC,iutA,iroN, EC232_ST73C 73 None detected iroC,iutA,iroN,iucA,iucC,iucD,iroD,iroB,iroE,iucB,sitA,sitC,sitD,sitB,iss EC230_ST91C 91 repA_FIB sitA,sitC,sitD,sitB,iss EC12_ST131H 131 repA1_FII iutA,iucA,iucC,iucD,iucB,sitA,sitC,sitD,sitB,iss Asterisk (*) on ‘isolate identifiers’ indicates linkage of repA with virulence genes on the same genomic scaffold (detailed in File S5). Virulence genes highlighted in bold fonts indicate genes that were assembled on a single scaffold with the repA gene, indicating linkage. A dollar ($) sign in the pCERC-4 rep gene column represents ≥95 % but not 100 % identity with the respective rep gene sequence. We also identified an IncI1 replicon in six isolates (four associated with HO and two with CO infections), four of which had an ISEcp1 associated with bla CTX-M-15 (Table 1) gene. An IncX4 replicon was identified in five isolates, three of which were ST131. Finally, an IncQ replicon was identified in three MDR isolates belonging to ST38, ST349 and ST88.

Discussion

This study and others show that BSIs are caused by genetically diverse [56], indicating that pathogen virulence profiles and perhaps host immune status are likely to be important variables in disease causation. ST131, often isolated from patients with BSI, is widely disseminated in Europe, Asia, North America, Africa and Australia [32, 57], and has played a critical role in the global spread of bla CTX-M-15 [58]. Our data show that bla CTX-M-15 in BSIs in Sydney is not restricted to ST131 but extends to ST8196, ST393 and ST38. Chromosomal bla CTX-M-15 in ST131 is usually associated with ISEcpI elements, but in EC44_ST131, EC46_ST131 and EC66_ST393, bla CTX-M-15 is not linked to ISEcpI, suggesting a different genetic context, including an association with other plasmids. Although our data are based on a limited number of isolates acquired from a single hospital in Sydney, they highlight similar population dynamics in the context of resistance and virulence genes found in invasive isolates reported on a cohort of more than 1500 collected over 11 years in the UK [57]. The number of virulence genes carried by ST131 was - less than that in the cohort of ST73 (Fig. 3, Files S3 and S4), suggesting that there is segregation between excessively virulent and extremely drug-resistant clonal lineages [59]. However, acquisition of virulence plasmids such as ColV that carry CRLs may alter this scenario, necessitating constant surveillance to identify emerging resistance threats [52]. While lineages of ST73 with MDR genotypes are commonly described, drug-sensitive lineages and lineages devoid of plasmids in Australia are also documented [60]. IncFII and IncFIB plasmid replicons were abundant in genetically diverse isolates acquired from both CO and HO BSIs. Virulence gene profiling studies suggested that a subset of isolates with ST95, ST131 and others likely carry an IncFII–IncFIB plasmid. Plasmids that have the ColV operon associated with IncF transfer regions often harbour a combination of virulence genes linked to serious human and animal diseases [24, 54, 61–65]. Based on an animal model of UPEC disease, it was demonstrated that acquisition of ColV-like plasmid and associated virulence genes influence disease aetiology [66, 67]. In addition, the acquisition of a ColV-like plasmid by serovar Kentucky has been purported to be a key genetic event that transformed its ability to cause serious disease in poultry by conferring new colonization and fitness capabilities [24]. ColV plasmids are implicated in invasive avian diseases, such as colibacillosis caused by avian pathogenic (APEC) in commercial poultry, and are considered to be a defining trait of the ExPEC sub-pathotype [13, 61]. These plasmids carry an extensive suite of VAGSs necessary for colonization and disease formation in diverse hosts, including humans. Gene products that mediate increased serum survival (iss), membrane vesicle formation protein (encoded by hlyF gene), outer-membrane protease activity (encoded by ompT), aerobactin biosynthesis (iuc operon), temperature-sensitive haemagglutination (encoded by tsh) and various (sit, iroN and eit) iron acquisition systems [5, 55] are significant in this regard. Our blastn analysis with assembled genomes supported initial observations from mapping of raw Illumina reads against two hybrid IncFII–IncFIB–ColV plasmids, indicating the presence of genes in the ColV operon in EC11_ST95, EC152_ST95C, EC123_ST88C and EC357_ST131C. Strains carrying the ColV operon and col-Ia genes included EC104_ST95C, EC177_ST95H, EC120_ST131C, EC337_ST69H, EC236_ST540C and EC25_ST88H. Our data also indicate that there are variabilities in the IncF plasmids circulating in our BSI cohort [54] and some may carry different combinations of the colV operon, col-Ia genes and a repertoire of virulence genes- the three features that define typical hybrid ColV plasmids. Further studies using long-read sequencing methodologies are required to address the diversity of plasmids carrying ColV-like virulence gene cargo and examine their associations with antibiotic resistance genes . Forty-seven isolates in the bacteraemia cohort (58 %) carry a class 1 integron (Table 1). As expected, most of the intI1-positive isolates carried a larger number of antibiotic resistance genes compared to isolates that did not have a class 1 integron. Almost all with intI1 carried a minimum set of genes encoding resistance to streptomycin (aadA gene cassettes) and/or trimethoprim (dfrA gene cassettes), sulphonamide drugs (sul1, sul2 or sul3 genes) and ampicillin (bla TEM-1). Most isolates (34/49; 73 %) that displayed phenotypic resistances to trimethoprim, used commonly as a first-line treatment option for uncomplicated UTIs, also had a sulphonamide resistance gene associated with the class 1 integron in the CRL. The class 1 integron is inarguably one the most successful genetic elements responsible for the rapid evolution of multiple drug resistance, as it has captured a wide array of resistance gene cassettes [68] and dispersed within diverse animal and plant commensals and pathogensin every continent [69]. The structural boundaries that define class 1 integrons continue to evolve, often mediated by insertion of other mobile genetic elements such as IS26 [70-74] that is well documented to mobilize diverse antibiotic resistance genes. Class 1 integrons are found on various plasmid backbones, including conjugative broad-host-range plasmids, and is widely considered to be a reliable proxy for identification of multiple drug-resistant genomes [16, 75]. The MDR isolates in this cohort exhibited little diversity in the carriage of cassette-associated genes. Most class 1 integrons appeared to be variants of In2 or In4, some of which were associated with Tn21/Tn1721 hybrid transposon backbones. Our data identified IS26 adjacent to resistance genes in most of the CRLs (Fig. 3) and their presence creates scaffold breaks in the assembly of genome sequences. We also provide evidence for multiple IS26 elements per genome (Table 1), reinforcing the role played by IS26 in driving the evolution of multidrug resistant phenotypes in the Enterobacterales, including those causing BSIs. This is a critically important observation because: (i) IS26 can mobilize a wide range of antibiotic resistance genes; (ii) IS26 is a preferred site for integration of translocatable units (TUs) ; and (iii) CRLs flanked by IS26 have the capacity to move laterally as independent TUs [76]. These observations emphasize the necessity for targeting mobile resistance scaffolds in developing and implementing comprehensive surveillance protocols for resistance gene epidemiology. Integration of such real-time surveillance data on the mobile resistome of pathogen and commensal populations in healthcare settings will better assist infection control teams to identify hotspots for the evolution of MDR pathogens. One of the most significant findings from this study is the identification of ST8196 within the ST131 clonal complex. ST8196 isolates shared similar genotypic, phenotypic and plasmid profiles with ST131 isolates in the cohort. Both ST8196 isolates were identified from the 2014 sample pool and displayed resistance to multiple antibiotics, carriage of bla CTX-M-15 and chromosomal parC and gyrB mutations known to confer fluoroquinolone resistance (Table 1). In addition, the ST8196 isolates have acquired a plasmid-associated qnrB4 gene. The isolation of ST8196 with plasmid-encoded qnrB4 genes indicates that active surveillance for this ST is needed in Sydney and Australia more broadly. In conclusion, MDR isolates in this genetically diverse BSI cohort exhibit limited variation in class 1 integron structure and in the cassette arrays they carry. IS26 is playing a significant role in shaping the composition of genes in the CRLs, which mostly include class 1 integrons in pathogenic . The role played by IS26 in the evolution of CRL is significant because they present furtheropportunities to rapidly acquire antibiotic resistance genes, including ones encoding resistance to clinically important antibiotics. We have identified in this cohort of isolates from BSIs that carry the plasmid-associated fluoroquinolone resistance gene qnrB4 and bla CTX-M-15. Dissemination of such plasmids may contribute to the rapid rise of co-resistance to two clinically important groups of antibiotics. Finally, IncF plasmids are important in the evolution of resistance and virulence attributes in causing BSIs in Australia. A detailed investigation of the plasmids that circulate in causing bacteraemia is warranted.

Data Bibliography

GenBank accession number for reference genomes used in this manuscript were U00096.2 (E. coli K12), NZ_HG941718.1 (E. coli EC958), CP000647.1 (Klebsiella pneumoniae subsp. pneumoniae MGH78578) and plasmid sequence ID KU578032 (pCERC-4) and MH195200.1 (pSDJ2009-52F). Click here for additional data file. Click here for additional data file.
  68 in total

1.  Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli.

Authors:  Eva Moreno; Guillem Prats; Montserrat Sabaté; Teresa Pérez; James R Johnson; Antonia Andreu
Journal:  J Antimicrob Chemother       Date:  2006-01-03       Impact factor: 5.790

Review 2.  Host specificity of septicemic Escherichia coli: human and avian pathogens.

Authors:  Eliora Z Ron
Journal:  Curr Opin Microbiol       Date:  2005-12-27       Impact factor: 7.934

3.  Population structure of Escherichia coli causing bacteraemia in the UK and Ireland between 2001 and 2010.

Authors:  M J Day; M Doumith; J Abernethy; R Hope; R Reynolds; J Wain; D M Livermore; N Woodford
Journal:  J Antimicrob Chemother       Date:  2016-05-05       Impact factor: 5.790

4.  A commensal gone bad: complete genome sequence of the prototypical enterotoxigenic Escherichia coli strain H10407.

Authors:  Lisa C Crossman; Roy R Chaudhuri; Scott A Beatson; Timothy J Wells; Mickael Desvaux; Adam F Cunningham; Nicola K Petty; Vivienne Mahon; Carl Brinkley; Jon L Hobman; Stephen J Savarino; Susan M Turner; Mark J Pallen; Charles W Penn; Julian Parkhill; A Keith Turner; Timothy J Johnson; Nicholas R Thomson; Stephen G J Smith; Ian R Henderson
Journal:  J Bacteriol       Date:  2010-08-27       Impact factor: 3.490

5.  Comparison of extraintestinal pathogenic Escherichia coli strains from human and avian sources reveals a mixed subset representing potential zoonotic pathogens.

Authors:  Timothy J Johnson; Yvonne Wannemuehler; Sara J Johnson; Adam L Stell; Curt Doetkott; James R Johnson; Kwang S Kim; Lodewijk Spanjaard; Lisa K Nolan
Journal:  Appl Environ Microbiol       Date:  2008-09-26       Impact factor: 4.792

6.  Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis.

Authors:  M Ananias; T Yano
Journal:  Braz J Med Biol Res       Date:  2008-10       Impact factor: 2.590

7.  The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups.

Authors:  Olivier Clermont; Julia K Christenson; Erick Denamur; David M Gordon
Journal:  Environ Microbiol Rep       Date:  2012-12-24       Impact factor: 3.541

8.  A role for Tn6029 in the evolution of the complex antibiotic resistance gene loci in genomic island 3 in enteroaggregative hemorrhagic Escherichia coli O104:H4.

Authors:  Piklu Roy Chowdhury; Ian G Charles; Steven P Djordjevic
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

9.  Antimicrobial resistance patterns and integron carriage of Escherichia coli isolates causing community-acquired infections in Turkey.

Authors:  Aysegul Copur-Cicek; Osman Birol Ozgumus; Aysegul Saral; Cemal Sandalli
Journal:  Ann Lab Med       Date:  2014-02-13       Impact factor: 3.464

10.  Clonal ST131-H22 Escherichia coli strains from a healthy pig and a human urinary tract infection carry highly similar resistance and virulence plasmids.

Authors:  Cameron J Reid; Jessica McKinnon; Steven P Djordjevic
Journal:  Microb Genom       Date:  2019-09-12
View more
  16 in total

1.  Escherichia coli ST8196 is a novel, locally evolved, and extensively drug resistant pathogenic lineage within the ST131 clonal complex.

Authors:  Priyanka Hastak; Mathieu Fourment; Aaron E Darling; Thomas Gottlieb; Elaine Cheong; John Merlino; Garry S A Myers; Steven P Djordjevic; Piklu Roy Chowdhury
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

2.  Genomic comparisons of Escherichia coli ST131 from Australia.

Authors:  Dmitriy Li; Ethan R Wyrsch; Paarthiphan Elankumaran; Monika Dolejska; Marc S Marenda; Glenn F Browning; Rhys N Bushell; Jessica McKinnon; Piklu Roy Chowdhury; Nola Hitchick; Natalie Miller; Erica Donner; Barbara Drigo; Dave Baker; Ian G Charles; Timothy Kudinha; Veronica M Jarocki; Steven Philip Djordjevic
Journal:  Microb Genom       Date:  2021-12

3.  Carriage of antibiotic resistant bacteria in endangered and declining Australian pinniped pups.

Authors:  Mariel Fulham; Fiona McDougall; Michelle Power; Rebecca R McIntosh; Rachael Gray
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.240

4.  F Plasmid Lineages in Escherichia coli ST95: Implications for Host Range, Antibiotic Resistance, and Zoonoses.

Authors:  Max Laurence Cummins; Cameron J Reid; Steven Philip Djordjevic
Journal:  mSystems       Date:  2022-01-25       Impact factor: 6.496

5.  Ten-year longitudinal molecular epidemiology study of Escherichia coli and Klebsiella species bloodstream infections in Oxfordshire, UK.

Authors:  Ann Sarah Walker; Nicole Stoesser; Samuel Lipworth; Karina-Doris Vihta; Kevin Chau; Leanne Barker; Sophie George; James Kavanagh; Timothy Davies; Alison Vaughan; Monique Andersson; Katie Jeffery; Sarah Oakley; Marcus Morgan; Susan Hopkins; Timothy E A Peto; Derrick W Crook
Journal:  Genome Med       Date:  2021-09-03       Impact factor: 15.266

6.  Characterization of beta-lactam-resistant Escherichia coli from Australian fruit bats indicates anthropogenic origins.

Authors:  Fiona K McDougall; Wayne S J Boardman; Michelle L Power
Journal:  Microb Genom       Date:  2021-05

7.  Genomic Characterisation of a Multiple Drug Resistant IncHI2 ST4 Plasmid in Escherichia coli ST744 in Australia.

Authors:  Tiziana Zingali; Toni A Chapman; John Webster; Piklu Roy Chowdhury; Steven P Djordjevic
Journal:  Microorganisms       Date:  2020-06-14

8.  Snapshot Study of Whole Genome Sequences of Escherichia coli from Healthy Companion Animals, Livestock, Wildlife, Humans and Food in Italy.

Authors:  Elisa Massella; Cameron J Reid; Max L Cummins; Kay Anantanawat; Tiziana Zingali; Andrea Serraino; Silvia Piva; Federica Giacometti; Steven P Djordjevic
Journal:  Antibiotics (Basel)       Date:  2020-11-06

9.  Epidemic HI2 Plasmids Mobilising the Carbapenemase Gene blaIMP-4 in Australian Clinical Samples Identified in Multiple Sublineages of Escherichia coli ST216 Colonising Silver Gulls.

Authors:  Hassan Tarabai; Ethan R Wyrsch; Ibrahim Bitar; Monika Dolejska; Steven P Djordjevic
Journal:  Microorganisms       Date:  2021-03-10

10.  Ten Years of Population-Level Genomic Escherichia coli and Klebsiella pneumoniae Serotype Surveillance Informs Vaccine Development for Invasive Infections.

Authors:  Samuel Lipworth; Karina-Doris Vihta; Kevin K Chau; James Kavanagh; Timothy Davies; Sophie George; Leanne Barker; Ali Vaughan; Monique Andersson; Katie Jeffery; Sarah Oakley; Marcus Morgan; Timothy E A Peto; Derrick W Crook; A Sarah Walker; Nicole Stoesser
Journal:  Clin Infect Dis       Date:  2021-12-16       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.